165 related articles for article (PubMed ID: 30548075)
1. Total Synthesis of Archazolid F.
Scheeff S; Menche D
Org Lett; 2019 Jan; 21(1):271-274. PubMed ID: 30548075
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and activity of the archazolid western hemisphere.
Tran AB; Melly GC; Doucette R; Ashcraft B; Sebren LJ; Havko N; Young JC; O'Neil GW
Org Biomol Chem; 2011 Oct; 9(22):7671-4. PubMed ID: 21931924
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of a water-soluble derivative of the potent V-ATPase inhibitor archazolid.
Persch E; Basile T; Bockelmann S; Huss M; Wieczorek H; Carlomagno T; Menche D
Bioorg Med Chem Lett; 2012 Dec; 22(24):7735-8. PubMed ID: 23122818
[TBL] [Abstract][Full Text] [Related]
4. Modular total synthesis of archazolid A and B.
Menche D; Hassfeld J; Li J; Mayer K; Rudolph S
J Org Chem; 2009 Oct; 74(19):7220-9. PubMed ID: 19739663
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of Novel Potent Archazolids: Pharmacology of an Emerging Class of Anticancer Drugs.
Scheeff S; Rivière S; Ruiz J; Abdelrahman A; Schulz-Fincke AC; Köse M; Tiburcy F; Wieczorek H; Gütschow M; Müller CE; Menche D
J Med Chem; 2020 Feb; 63(4):1684-1698. PubMed ID: 31990540
[TBL] [Abstract][Full Text] [Related]
6. Stereochemical determination of Archazolid A and B, highly potent vacuolar-type ATPase inhibitors from the Myxobacterium Archangium gephyra.
Hassfeld J; Farès C; Steinmetz H; Carlomagno T; Menche D
Org Lett; 2006 Oct; 8(21):4751-4. PubMed ID: 17020294
[TBL] [Abstract][Full Text] [Related]
7. Archazolid A-15-O-β-D-glucopyranoside and iso-archazolid B: potent V-ATPase inhibitory polyketides from the myxobacteria Cystobacter violaceus and Archangium gephyra.
Horstmann N; Essig S; Bockelmann S; Wieczorek H; Huss M; Sasse F; Menche D
J Nat Prod; 2011 May; 74(5):1100-5. PubMed ID: 21513292
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
[TBL] [Abstract][Full Text] [Related]
9. EPR Studies of V-ATPase with Spin-Labeled Inhibitors DCC and Archazolid: Interaction Dynamics with Proton Translocating Subunit c.
Gölz JP; Bockelmann S; Mayer K; Steinhoff HJ; Wieczorek H; Huss M; Klare JP; Menche D
ChemMedChem; 2016 Feb; 11(4):420-8. PubMed ID: 26662886
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis and Biological Evaluation of Highly Potent Simplified Archazolids.
Rivière S; Vielmuth C; Ennenbach C; Abdelrahman A; Lemke C; Gütschow M; Müller CE; Menche D
ChemMedChem; 2020 Jul; 15(14):1348-1363. PubMed ID: 32363789
[TBL] [Abstract][Full Text] [Related]
11. The vacuolar-type ATPase inhibitor archazolid increases tumor cell adhesion to endothelial cells by accumulating extracellular collagen.
Luong B; Schwenk R; Bräutigam J; Müller R; Menche D; Bischoff I; Fürst R
PLoS One; 2018; 13(9):e0203053. PubMed ID: 30204757
[TBL] [Abstract][Full Text] [Related]
12. Lobatamide C: total synthesis, stereochemical assignment, preparation of simplified analogues, and V-ATPase inhibition studies.
Shen R; Lin CT; Bowman EJ; Bowman BJ; Porco JA
J Am Chem Soc; 2003 Jul; 125(26):7889-901. PubMed ID: 12823009
[TBL] [Abstract][Full Text] [Related]
13. Archazolid A binds to the equatorial region of the c-ring of the vacuolar H+-ATPase.
Bockelmann S; Menche D; Rudolph S; Bender T; Grond S; von Zezschwitz P; Muench SP; Wieczorek H; Huss M
J Biol Chem; 2010 Dec; 285(49):38304-14. PubMed ID: 20884613
[TBL] [Abstract][Full Text] [Related]
14. V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.
Kubisch R; Fröhlich T; Arnold GJ; Schreiner L; von Schwarzenberg K; Roidl A; Vollmar AM; Wagner E
Int J Cancer; 2014 May; 134(10):2478-88. PubMed ID: 24166050
[TBL] [Abstract][Full Text] [Related]
15. Selective upregulation of TNFα expression in classically-activated human monocyte-derived macrophages (M1) through pharmacological interference with V-ATPase.
Thomas L; Rao Z; Gerstmeier J; Raasch M; Weinigel C; Rummler S; Menche D; Müller R; Pergola C; Mosig A; Werz O
Biochem Pharmacol; 2017 Apr; 130():71-82. PubMed ID: 28189727
[TBL] [Abstract][Full Text] [Related]
16. Archazolid and apicularen: novel specific V-ATPase inhibitors.
Huss M; Sasse F; Kunze B; Jansen R; Steinmetz H; Ingenhorst G; Zeeck A; Wieczorek H
BMC Biochem; 2005 Aug; 6():13. PubMed ID: 16080788
[TBL] [Abstract][Full Text] [Related]
17. Understanding the inhibitory effect of highly potent and selective archazolides binding to the vacuolar ATPase.
Dreisigacker S; Latek D; Bockelmann S; Huss M; Wieczorek H; Filipek S; Gohlke H; Menche D; Carlomagno T
J Chem Inf Model; 2012 Aug; 52(8):2265-72. PubMed ID: 22747331
[TBL] [Abstract][Full Text] [Related]
18. Total synthesis of bafilomycin A1.
Kleinbeck F; Fettes GJ; Fader LD; Carreira EM
Chemistry; 2012 Mar; 18(12):3598-610. PubMed ID: 22344969
[TBL] [Abstract][Full Text] [Related]
19. Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.
Zhang S; Schneider LS; Vick B; Grunert M; Jeremias I; Menche D; Müller R; Vollmar AM; Liebl J
Oncotarget; 2015 Dec; 6(41):43508-28. PubMed ID: 26496038
[TBL] [Abstract][Full Text] [Related]
20. Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B.
Hamm R; Sugimoto Y; Steinmetz H; Efferth T
Invest New Drugs; 2014 Oct; 32(5):893-903. PubMed ID: 25065443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
